Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001
BOSTON, May 30, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today announced that it has completed the initial dosing in healthy volunteers (HV) in its clinical trial for BBT002, a novel, half-life extended bispecific antibody designed as a 'platform in a molecule' with broad applications across respiratory, dermatology, and gastroenterology.
The Phase 1 clinical trial (BBT002-001; NCT06944925 ) is a randomized, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study evaluating BBT002 in healthy volunteers and adults with COPD. The study will evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary efficacy of BBT002. Approximately 96 participants are expected to enroll across multiple sites. Interim safety and pharmacokinetic data are anticipated in the first quarter of 2026. Bambusa is also considering expanding into additional indications including asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, eosinophilic esophagitis and food allergy, to fully realize the 'platform-in-a-molecule' potential for BBT002.
'Advancing our second program into the clinic within just 12 months of founding Bambusa reflects the speed, precision, and high standards that define our development culture,' said Thang Ho, PhD, Senior Vice President of Development Sciences at Bambusa Therapeutics. 'BBT002's dual-target mechanism leverages two of the most classic and fundamental inflammatory pathways—enabling a rational, biology-driven approach to push the efficacy ceiling beyond what single-target therapies can achieve. We believe this strategy may offer additive or synergistic benefit, particularly for patients with complex, multi-organ inflammatory diseases. This milestone highlights our team's ability to rapidly translate bold science into clinical-stage programs with broad impact.'
Separately, Bambusa also announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to proceed with the clinical development of BBT001, a novel multi-targeting, half-life extended bispecific antibody for the treatment of atopic dermatitis and other inflammatory skin diseases. BBT001 is currently being studied in a randomized, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study conducted in Australia, evaluating BBT001 in healthy volunteers and adults with moderate to severe atopic dermatitis.
About Bambusa's pipeline
BBT001 is a novel half-life extended bispecific antibody. Preclinical data with BBT001 demonstrate its best-in-disease potential, offering enhanced efficacy and improved dosing convenience compared to approved biologics in atopic dermatitis. It is currently being tested in a Phase I clinical study (BBT001-001; NCT06808477)
BBT002 is a novel half-life extended bispecific antibody designed as a 'platform in a molecule' with broad applications across respiratory, dermatology, and gastroenterology indications. Preclinical data with BBT002 demonstrate its best-in-disease potential, offering enhanced efficacy and improved dosing convenience compared to approved biologics across multiple inflammatory conditions. It is currently being tested in a Phase I clinical study (BBT002-001; NCT06944925 ).
The company's additional pipeline candidates, BBT003 and BBT004, are being developed for inflammatory bowel disease and rheumatological conditions, each with best-in-disease potential.
About Bambusa Therapeutics
Bambusa Therapeutics is a clinical-stage biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, Bambusa's mission is to advance the field of immunology with cutting-edge solutions. For more information, visit www.bambusatx.com.
View original content to download multimedia: https://www.prnewswire.com/news-releases/bambusa-therapeutics-announces-first-subject-dosed-in-phase-1-clinical-trial-of-bbt002-a-novel-platform-in-a-molecule-bispecific-antibody-for-broad-ii-conditions-and-us-fda-clearance-of-ind-application-for-bbt001-302469224.html
SOURCE Bambusa Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Stay hurricane-ready with Storm Team 3's 2025 Hurricane Guide
SAVANNAH, Ga. (WSAV) — The 2025 Atlantic hurricane season is here. National forecasters are predicting an above-normal season, with the possibility of 13 to 19 total named storms. Six to ten of those are expected to develop into hurricanes, with three to five of them becoming major hurricanes. Storm Team 3 is On Your side with their updated Hurricane-Ready Guide to help you prepare for whatever comes our way this season. Are shelters available? How should I prepare my property? What evacuation route do I take. This guide details that and much more. Be sure to print a copy or download it to your phone for easy access to critical information. WSAV Hurricane-Safety Guide 2025Download Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
How to keep infections and germs from spreading at the gym
(WKBN) – If you joined a gym or plan to this summer, it's important to clean any equipment you use. Some people might not know that germs can spread this way. Doctors say you can get infections from touching skin or using shared equipment. To lower your risk, wipe down any equipment with disinfectant spray. Most gyms have spray and wipes available. It's also a good idea to shower when you get home. Dr. Donald Dumford, an infectious disease specialist at the Cleveland Clinic, warns that we should be careful of other germs, too. 'We do have to think about the fact that the gym is a shared airspace, so you do put yourself at risk for the possibility of viruses such as flu, cold viruses, COVID, RSV. So really, if you are feeling ill, if you're having a fever, if you're having a cough, consider staying home from the gym until your symptoms are improved,' he said. Dumford says if you see anything unusual on your skin, like redness, itching or swelling, it's best to see a doctor. There are different treatments you can try. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Blue Origin completes 12th human flight to space
EL PASO, Texas (KTSM) — Space technology company Blue Origin successfully completed its 12th human spaceflight and the 32nd flight for the New Shepard program on Saturday morning, May 31. The launch took place from the company's facility outside of Van Horn and took a human crew to the Karman line, the internationally recognized boundary of space. The crew included: K-12 STEM teacher Aymette Medina Jorge; radiologist turned explorer Dr. Gretchen Green; former Panamanian ambassador to the United States Jaime Alemán; businessman Jesse Williams; aerospace executive Mark Rocket; and entrepreneur Paul Jeris. Including Saturday's crew, New Shepard has now flown 64 people into space — including four who have flown twice — among them scientific researchers, educators, physicians, explorers, and entrepreneurs. 'We thank our customers for trusting us to give them the opportunity to appreciate Earth's fragility from above, an experience that truly transforms those who embark on it,' said Phil Joyce, senior vice president of New Shepard. 'We look forward to seeing what our remarkable crew will do with this experience. I am proud of our team's dedication in making these moments possible.' Here is what Blue Origin said about the New Shepard program: 'Named after astronaut Alan Shepard, the first American in space, New Shepard is Blue Origin's fully reusable, autonomous suborbital rocket system built to fly humans and scientific payloads to space. The rocket is powered by one BE-3PM engine, which is fueled by a highly efficient and clean combination of liquid hydrogen and oxygen. During flight, the only byproduct of New Shepard's engine combustion is water vapor, with no carbon emissions.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
